Cinemark (CNK) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks
31 Oct 2024

For the quarter ended September 2024, Cinemark Holdings (CNK) reported revenue of $921.8 million, up 5.4% over the same period last year. EPS came in at $1.19, compared to $0.61 in the year-ago quarter.

The reported revenue represents a surprise of +3.37% over the Zacks Consensus Estimate of $891.75 million. With the consensus EPS estimate being $0.58, the EPS surprise was +105.17%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cinemark performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Average ticket price - U.S. Operating Segment: $9.98 versus the three-analyst average estimate of $9.71.
  • Average ticket price - International Operating Segment: $3.74 versus $3.75 estimated by three analysts on average.
  • Concession revenues per patron - U.S. Operating Segment: $7.97 compared to the $7.48 average estimate based on three analysts.
  • Concession revenues per patron - International Operating Segment: $2.97 compared to the $2.91 average estimate based on three analysts.
  • Revenue- International Operating Segment- Admissions: $85.20 million compared to the $86.41 million average estimate based on two analysts. The reported number represents a change of -8.8% year over year.
  • Revenue- U.S. Operating Segment- Admissions: $375.20 million versus the two-analyst average estimate of $365.11 million. The reported number represents a year-over-year change of +7.1%.
  • Revenue- U.S. Operating Segment- Other: $42.20 million compared to the $64.63 million average estimate based on two analysts. The reported number represents a change of -34.2% year over year.
  • Revenue- U.S. Operating Segment- Concession: $299.60 million versus the two-analyst average estimate of $281.06 million. The reported number represents a year-over-year change of +11.8%.
  • Revenue- International Operating Segment- Other: $12.20 million versus the two-analyst average estimate of $26.05 million. The reported number represents a year-over-year change of -55%.
  • Revenue- Admissions: $460.40 million compared to the $452.34 million average estimate based on six analysts. The reported number represents a change of +3.7% year over year.
  • Revenue- Other: $94.10 million versus the six-analyst average estimate of $88.29 million. The reported number represents a year-over-year change of +3.2%.
  • Revenue- Concession: $367.30 million versus $351.14 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.1% change.
View all Key Company Metrics for Cinemark here>>>

Shares of Cinemark have returned +11.4% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cinemark Holdings Inc (CNK) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10